An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Deferasirox (Primary) ; Erythropoietin
- Indications Myelodysplastic syndromes
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 14 Feb 2017 Planned End Date changed from 1 May 2017 to 31 May 2017.
- 14 Feb 2017 Planned primary completion date changed from 1 May 2017 to 31 May 2017.